ストックスクリーナーアプリを入手
6.01
1.15%
-0.07
前日終値:
$6.08
開ける：
$6
24時間の取引高:
540.42K
Relative Volume:
0.89
時価総額：
$329.17M
収益：
$3.32M
当期純損益:
$-156.76M
株価収益率:
-2.0711
EPS:
-2.9019
ネットキャッシュフロー:
$-140.13M
1週間 パフォーマンス:
-10.16%
1か月 パフォーマンス:
-11.49%
6か月 パフォーマンス:
-22.95%
1年 パフォーマンス:
-69.46%
1日の値動き範囲:
$5.965
$6.23
1週間の範囲:
$5.77
$6.98
52週間の値動き範囲:
$5.77
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Compare UPB vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.01 | 375.18M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-18 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Evercore ISI | Outperform |
| 2025-10-14 | 開始されました | Truist | Buy |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
すべてを表示
Upstream Bio Inc (UPB) 最新ニュース
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase - GuruFocus
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - Kalkine
Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright - MarketBeat
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio, Inc. to drive physician engagement - Traders Union
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchInstitutional Buy Signals - Vinanet
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36 - Moomoo
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Upstream Bio Targets Q1 2027 Start for Phase - Minichart
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP - TradingView
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP - Bitget
Pstream Bio stock rises 2.6% after Q2 results and pipeline update - Traders Union
Form 8K Upstream Bio Inc For: 11 August By Investing.com - Investing.com Canada
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary - TradingView
Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash - Stock Titan
Upstream Bio Q2 net loss narrows slightly on lower R&D costs - TradingView
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
Upstream Bio Posts $39.7 Million Q2 Net Loss as Trials Advance - Quiver Quantitative
Upstream Bio, Inc. sets Phase 3 trial for sever asthma and CRSwNP in Q1 2027 - Traders Union
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress - Caledonian Record
Upstream Bio (UPB) Rises 0.94% to $7.51 as Biotech Stock Holds Key SupportAdvance Decline Volume - dars.gov.et
Upstream Bio Inc (UPB) Stock News Today - TradingKey
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Upstream Bio, Inc. (UPB) Stock Analysis: A Hidden Gem in Biotechnology with a 456% Potential Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB - MarketBeat
BlackRock, Inc. Trims Stake in Upstream Bio Inc (UPB) Amid Clini - GuruFocus
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Upstream Bio (UPB) Gains Ground: Testing Key Resistance Levels After 2.5% AdvanceBox Spread - dars.gov.et
Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Cash Flow - TradingKey
UPB|Upstream Bio Inc|Price:6.780|Chg%:+0.360 - TradingKey
UPB|Upstream Bio Inc|Price:6.400|Chg%:-0.010 - TradingKey
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Balance Sheet - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
UPB|Upstream Bio Inc|Price:7.450|Chg%:+0.200 - TradingKey
Upstream Bio Inc. (UPB) Holds Steady Near Support as Traders Eye Resistance BreakoutHigh Yield Stocks - dars.gov.et
Upstream Bio Inc (UPB) Income Statement - TradingKey
Upstream Bio, Inc. Revenue Breakdown – NASDAQ:UPB - TradingView
Upstream Bio (UPB) Holds Steady Near Support as Traders Eye Key Resistance LevelsRip Sell Trade - vinanet.vn
Decheng Capital LLC Sells 418,210 Shares of Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio Inc (UPB) 財務データ
収益
当期純利益
現金流量
EPS
Upstream Bio Inc (UPB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sutherland Everett Rand | Chief Executive Officer |
Jun 16 '26 |
Sale |
6.10 |
2,095 |
12,780 |
70,812 |
| Houghton Adam | Chief Business Officer |
Jun 16 '26 |
Sale |
6.10 |
700 |
4,270 |
23,601 |
| Deykin Aaron | Chief Medical Officer |
Jun 16 '26 |
Sale |
6.10 |
895 |
5,460 |
33,197 |
| Ambrose Allison | General Counsel |
Jun 16 '26 |
Sale |
6.10 |
477 |
2,910 |
16,048 |
| GRAY MICHAEL | CFO and COO |
Mar 16 '26 |
Sale |
9.29 |
852 |
7,915 |
29,648 |
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):